A review of picotamide in the reduction of cardiovascular events in diabetic patients

Picotamide is an antiplatelet drug with a dual inhibitory action. Thus, picotamide inhibits both thromboxane A2 (TxA2) receptors and TxA2 synthase and, at variance with aspirin, does not interfere with endothelial prostacyclin (PGI2) production. Two large randomized trials have been performed to assess the clinical efficacy of picotamide in patients at risk of atherothrombosis. The ADEP study compared peripheral artery disease (PAD) patients randomized to picotamide or placebo. This study did not show a significant reduction of cardiovascular events by picotamide but a subgroup analysis showed its potential usefulness in patients with diabetes. To investigate this issue further, the DAVID study recently enrolled diabetic patients with PAD randomized to picotamide versus aspirin; the results showed a significant reduction of overall mortality in the picotamide group. Moreover long-term picotamide treatment in diabetes promotes the reduction of microalbuminuria and the inhibition of growth of carotid plaques. These data suggest that picotamide may represent an interesting drug to be further investigated in future trials in the atherothrombotic setting.

[1]  D. Praticò,et al.  Thromboxane receptor blockade improves the antiatherogenic effect of thromboxane A2 suppression in LDLR KO mice. , 2007, Blood.

[2]  D. Angiolillo,et al.  The effects of oral anticoagulants in patients with peripheral arterial disease: rationale, design, and baseline characteristics of the Warfarin and Antiplatelet Vascular Evaluation (WAVE) trial, including a meta-analysis of trials. , 2006, American heart journal.

[3]  P. Gresele,et al.  Picotamide versus aspirin in diabetic patients with peripheral arterial disease: has David defeated Goliath? , 2004, European heart journal.

[4]  F. Violi,et al.  Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study. , 2004, European heart journal.

[5]  G. Lip,et al.  Antithrombotic therapy in peripheral arterial occlusive disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.

[6]  G. Panzram.  Mortality and survival in Type 2 (non-insulin-dependent) diabetes mellitus , 1987, Diabetologia.

[7]  D. Praticò,et al.  Inhibition by picotamide of thromboxane production in vitro and ex vivo , 2004, European Journal of Clinical Pharmacology.

[8]  F. Violi,et al.  Aspirin resistance and diabetic angiopathy: back to the future. , 2004, Thrombosis research.

[9]  G. Nenci,et al.  “In vitro” and “ex vivo” effects of picotamide, a combined thromboxane A2-synthase inhibitor and -receptor antagonist, on human platelets , 2004, European Journal of Clinical Pharmacology.

[10]  Z. Ungvari,et al.  Oxidative stress-induced isoprostane formation may contribute to aspirin resistance in platelets. , 2002, Prostaglandins, leukotrienes, and essential fatty acids.

[11]  A. Mattioli,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[12]  Catherine Sudlow,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[13]  J. Gamble,et al.  Roles of Cyclooxygenase (COX)-1 and COX-2 in Prostanoid Production by Human Endothelial Cells: Selective Up-Regulation of Prostacyclin Synthesis by COX-21 , 2001, The Journal of Immunology.

[14]  F. Squadrito,et al.  Effects of Picotamide on Release of Endothelin-1, Thromboxane, and Prostacycline After Treadmill Stress in Patients with Peripheral Artery Disease , 1998, Angiology.

[15]  A. Corsini,et al.  Picotamide, an antithromboxane agent, inhibits the migration and proliferation of arterial myocytes. , 1998, European journal of pharmacology.

[16]  G. Davı̀,et al.  Long-term treatment with the dual antithromboxane agent picotamide decreases microalbuminuria in normotensive type 2 diabetic patients. , 1998, Diabetes.

[17]  R. Tallarida,et al.  Antivasoconstrictor and Antiaggregatory Activities of Picotamide Unrelated to Thromboxane A2 Antagonism , 1997, Thrombosis and Haemostasis.

[18]  G. FitzGerald,et al.  Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[19]  G. Davı̀,et al.  Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease. , 1997, Circulation.

[20]  M. Milani,et al.  Effects of picotamide, an antiplatelet agent, on cardiovascular, events in 438 claudicant patients with diabetes: a retrospective analysis of the ADEP study. , 2003, British journal of clinical pharmacology.

[21]  R. Hamdy,et al.  Regulation of endothelin-1 production by a thromboxane A2 mimetic in rat heart smooth muscle cells. , 1996, Biochimica et biophysica acta.

[22]  M. Milani,et al.  Effects of picotamide, an antithromboxane agent, on carotid atherosclerotic evolution. A two-year, double-blind, placebo-controlled study in diabetic patients. , 1995, Stroke.

[23]  P. Modesti,et al.  Binding kinetics and antiplatelet activities of picotamide, a thromboxane A2 receptor antagonist , 1994, British journal of pharmacology.

[24]  F. Violi,et al.  Effect of Picotamide on the Clinical Progression of Peripheral Vascular Disease A Double‐Blind Placebo‐Controlled Study , 1993 .

[25]  FBalsano,et al.  Effect of picotamide on the clinical progression of peripheral vascular disease. A double-blind placebo-controlled study. The ADEP Group. , 1993 .

[26]  G. FitzGerald.  Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists. , 1991, The American journal of cardiology.

[27]  R. Abbate,et al.  Acute reduction of TxA2 platelet binding sites after in vivo administration of a TxA2 receptor inhibitor. , 1991, British journal of clinical pharmacology.

[28]  R. Abbate,et al.  Competitive inhibition of platelet thromboxane A2 receptor binding by picotamide. , 1989, European journal of pharmacology.

[29]  P. Gresele,et al.  Characterization of N,N’-bis(3-Picolyl)-4-Methoxy-Isophtalamide (Picotamide) as a Dual Thromboxane Synthase Inhibitor/Thromboxane A2 Receptor Antagonist in Human Platelets , 1989, Thrombosis and Haemostasis.

[30]  R. De Cristofaro,et al.  Effect of Picotamide on Prostacyclin Production by Human Endothelial Cells , 1988, Thrombosis and Haemostasis.

[31]  G. L. Le Breton,et al.  Arachidonic acid-induced platelet aggregation is mediated by a thromboxane A2/prostaglandin H2 receptor interaction. , 1984, The Journal of pharmacology and experimental therapeutics.

[32]  P. McNamara,et al.  Morbidity and Mortality in Diabetics In the Framingham Population: Sixteen Year Follow-up Study , 1974, Diabetes.